Limkain b1 Inhibitors
Chemical inhibitors of Limkain b1 can be understood through their action on various signaling pathways and kinases that are likely to interact with or influence Limkain b1 function. Staurosporine, a potent kinase inhibitor, directly targets the ATP binding site that is essential for the kinase activity of Limkain b1, which may result in the functional inhibition of this protein's enzymatic activity. Similarly, Bisindolylmaleimide I, which specifically inhibits Protein Kinase C (PKC), can reduce Limkain b1 activity by limiting phosphorylation-dependent interactions that Limkain b1 may be part of, given its role in cellular signaling. The MEK inhibitors U0126 and PD98059, by reducing ERK activity, can attenuate downstream signaling events that Limkain b1 might influence, thus indirectly inhibiting its function. LY294002 and Wortmannin, both inhibitors of PI3K, can decrease AKT pathway activity, which is a critical pathway for many cellular processes, possibly leading to a reduction in Limkain b1 activity due to lower phosphorylation levels and subsequent activation of downstream targets.
Furthermore, SP600125, by inhibiting JNK, can prevent activation of transcription factors and other proteins that could be necessary for Limkain b1's functional role, thus achieving indirect inhibition. SB203580, a p38 MAP kinase inhibitor, can also suppress Limkain b1 function by attenuating substrate activation within inflammatory signaling pathways in which Limkain b1 may be involved. The mTOR inhibitor Rapamycin can influence cellular processes that are critical for growth and metabolism, potentially affecting Limkain b1's role in these processes. Y-27632, a ROCK inhibitor, may lead to functional inhibition of Limkain b1 by altering the actin cytoskeleton dynamics, a cellular aspect that Limkain b1 could regulate. Inhibitors like Gefitinib and Imatinib, which target EGFR and various tyrosine kinases respectively, may affect Limkain b1 by altering the signaling landscape and cellular context in which Limkain b1 operates, leading to a decrease in its kinase activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Limkain b1, being a kinase, may be inhibited by Staurosporine through its action on the ATP binding site that is critical for Limkain b1's kinase activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits protein kinase C (PKC). Since PKC can phosphorylate substrates that may interact with Limkain b1, inhibition of PKC can reduce phosphorylation-dependent interactions, potentially reducing Limkain b1's functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Limkain b1, being associated with cellular signaling, could be indirectly inhibited if MEK is inhibited, as this would reduce ERK activity and downstream signaling events involving Limkain b1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, the AKT signaling pathway is downregulated, which could lead to reduced phosphorylation and activation of downstream targets, potentially resulting in the inhibition of Limkain b1's functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor. It functions similarly to LY294002, potentially reducing AKT pathway activity and therefore possibly inhibiting downstream effects on Limkain b1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in stress signaling pathways. By inhibiting JNK, SP600125 could prevent the activation of transcription factors and other proteins that may interact with Limkain b1, thereby inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which, like U0126, could indirectly inhibit Limkain b1 by reducing downstream ERK activity and thus affecting signaling pathways in which Limkain b1 is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibition of p38 kinase can lead to decreased activation of substrates involved in inflammatory response signaling, potentially inhibiting Limkain b1 function in these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central protein in cell growth and metabolism. By inhibiting mTOR, Rapamycin could influence Limkain b1's function indirectly, as mTOR signaling affects a variety of cellular processes that Limkain b1 could be involved in. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. Since ROCK can influence actin cytoskeleton dynamics and Limkain b1 is implicated in cytoskeletal regulation, inhibition of ROCK could lead to an indirect functional inhibition of Limkain b1. | ||||||